NCLT reserves order for Dabur India's proposed Sesa Care amalgamation
NCLT New Delhi Bench reserved order for Dabur India-Sesa Care amalgamation on August 24, 2026. Statutory authorities recorded no-objection to the sanctioning of the scheme. Scheme falls under Sections 230 to 232 of the Companies Act, 2013. Company to notify exchanges upon receipt of final NCLT order.

*this image is generated using AI for illustrative purposes only.
The National Company Law Tribunal (NCLT), New Delhi Bench, has reserved its order regarding the proposed scheme of amalgamation between Dabur India and Sesa Care Private Limited. The tribunal will formally pronounce the order following the second motion petition hearing held on August 24, 2026.
This development follows a series of regulatory approvals and intimations issued by the company since May 2025. The statutory authorities have recorded their no-objection to the sanctioning of the scheme under Sections 230 to 232 of the Companies Act, 2013.
Regulatory Progress
The amalgamation involves Sesa Care Private Limited as the transferor company and Dabur India Limited as the transferee company. The process includes the consolidation of shareholders and creditors from both entities.
Dabur India has notified the stock exchanges of the reserved order status. The company stated it will issue further notifications and update its website upon receipt of the final copy of the NCLT order. This disclosure was made in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Historical Stock Returns for Dabur India
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.51% | -1.68% | -6.49% | -22.53% | -22.74% | -34.67% |
How is the final NCLT order expected to impact Dabur India's short-term stock price volatility and long-term valuation metrics?
What specific operational synergies or cost-saving measures does Dabur anticipate realizing from integrating Sesa Care's assets and workforce?
Will the amalgamation alter Dabur's strategic focus on its healthcare segment, potentially shifting resource allocation away from core FMCG products?


































